Pharmacophore Virtual Screening Identifies Riboflavin as an Inhibitor of the Schistosome Cathepsin B1 Protease with Antiparasitic Activity

Autor(es):Mostrar menos -

Cogo, Ramon M. ; Pavani, Thais F. A. ; Mengarda, Ana C. A. ; Cajas, Rayssa A. ; Teixeira, Thaina R. ; Fukui-Silva, Lucas ; Sun, Yujie Uli ; Liu, Lawrence J. ; Amarasinghe, Dilini K. ; Yoon, Michael C. ; Santos-Filho, Osvaldo A. ; de Moraes, Josue ; Caffrey, Conor R. ; Rando, Daniela G. G.

• Tipo de documento: Artigo Científico
• Fonte: ACS OMEGA; v. 9, n. 23, p. 14-pg., 2024-05-30.

Resumo

Schistosomiasis is a neglected disease of poverty that affects over 200 million people worldwide and relies on a single drug for therapy. The cathepsin B1 cysteine protease (SmCB1) of Schistosoma mansoni has been investigated as a potential target. Here, a structure-based pharmacophore virtual screening (VS) approach was used on a data set of approved drugs to identify potential antischistosomal agents targeting SmCB1. Pharmacophore (PHP) models underwent validation through receiver operating characteristics curves achieving values >0.8. The data highlighted riboflavin (RBF) as a compound of particular interest. A 1 mu s molecular dynamics simulation demonstrated that RBF altered the conformation of SmCB1, causing the protease's binding site to close around RBF while maintaining the protease's overall integrity. RBF inhibited the activity of SmCB1 at low micromolar values and killed the parasite in vitro. Finally, in a murine model of S. mansoni infection, oral administration of 100 mg/kg RBF for 7 days significantly decreased worm burdens by similar to 20% and had a major impact on intestinal and fecal egg burdens, which were decreased by similar to 80%. (AU)

• Processo FAPESP: 16/22488-3 - Reposicionamento de fármacos para doenças negligenciadas: identificação de novos agentes anti-helmínticos
• Beneficiário: Josué de Moraes
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 23/08418-6 - Busca de metabólitos bioativos oriundos da biodiversidade brasileira como candidatos a fármacos para doenças causadas por helmintos
• Beneficiário: Josué de Moraes
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 19/26686-2 - Catepsina B1 de Schistosoma mansoni: design e síntese racional de potenciais inibidores
• Beneficiário: Daniela Goncales Galasse Rando
• Modalidade de apoio: Auxílio à Pesquisa - Regular